Pharmacological approaches in the treatment and maintenance of weight loss

Diabetes Care

Volumn 39, Issue , 2016, Pages S260-S267

  Van Gaal, Luc ^a   Dirinck, Eveline ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIOBESITY AGENT; LIRAGLUTIDE; LORCASERIN; NALTREXONE; PHENTERMINE PLUS TOPIRAMATE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ABDOMINAL PAIN; ADVERSE DRUG REACTION; ARTICLE; BACKACHE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; GLYCEMIC CONTROL; HEADACHE; HIGH RISK POPULATION; HUMAN; INSOMNIA; LIFESTYLE MODIFICATION; LOW CALORY DIET; METABOLIC PARAMETERS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARESTHESIA; PSYCHOLOGICAL ASPECT; RHINOPHARYNGITIS; RISK REDUCTION; SLEEP DISORDER; STEATORRHEA; SUSTAINED RELEASE FORMULATION; TACHYCARDIA; TREATMENT RESPONSE; VERY LOW CALORY DIET; VOMITING; WEIGHT CONTROL; WEIGHT REDUCTION; XEROSTOMIA; CALORIC RESTRICTION; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; COMPLICATION; DIET THERAPY; DRUG EFFECTS; LIFESTYLE; MAINTENANCE CHEMOTHERAPY; OVERWEIGHT; PROCEDURES; TRENDS;

ANTI-OBESITY AGENTS; CALORIC RESTRICTION; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; LIFE STYLE; MAINTENANCE CHEMOTHERAPY; OBESITY; OVERWEIGHT; WEIGHT LOSS;

EID: 84979523427     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dcS15-3016     Document Type: Article

References (71)

1. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875-880
2. Van Gaal LF, De Block CE. Bariatric surgery to treat type 2 diabetes: what is the recent evidence? Curr Opin Endocrinol Diabetes Obes 2012;19:352-358
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38:140-149
4. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011;365: 1597-1604
5. de Luis DA, Gonzalez Sagrado M, Conde R, Aller R, Izaola O. Decreased basal levels of glucagon-like peptide-1 after weight loss in obese subjects. Ann Nutr Metab 2007;51:134-138
6. Rosenbaum M, Leibel RL. 20 years of leptin: role of leptin in energy homeostasis in humans. J Endocrinol 2014;223:T83-T96
7. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
8. Wing RR; Look AHEAD Research Group. Longterm effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170:1566-1575
9. Wing RR, Lang W, Wadden TA, et al.; Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011;34:1481-1486
10. Rubin RR, Wadden TA, Bahnson JL, et al.; Look AHEAD Research Group. Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial. Diabetes Care 2014;37: 1544-1553
11. Foster GD, Borradaile KE, Sanders MH, et al.; Sleep AHEAD Research Group of Look AHEAD Research Group. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med 2009;169:1619-1626
12. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study. Obesity (Silver Spring) 2014;22:5-13
13. Pi-Sunyer FX. Weight loss in type 2 diabetic patients. Diabetes Care 2005;28:1526-1527
14. Phelan S, Wing RR, Loria CM, Kim Y, Lewis CE. Prevalence and predictors of weight-loss maintenance in a biracial cohort: results from the coronary artery risk development in young adults study. Am J Prev Med 2010;39:546-554
15. Berne C; Orlistat Swedish Type 2 diabetes Study Group. A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin. Diabet Med 2005;22: 612-618
16. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012;20:1426-1436
17. Garvey WT, Ryan DH, Bohannon NJ, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care 2014;37:3309-3316
18. Smith SR, Weissman NJ, Anderson CM, et al.; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebocontrolled trial of lorcaserin for weight management. N Engl J Med 2010;363:245-256
19. Derosa G, Cicero AF, D'Angelo A, Fogari E, Maffioli P. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. J Clin Pharm Ther 2012;37:187-195
20. Rodgers RJ, Tschöp MH, Wilding JP. Antiobesity drugs: past, present and future. Dis Model Mech 2012;5:621-626
21. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-161
22. Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab 2009;11: 361-371
23. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M; OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long-termefficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004;28:1399-1410
24. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:1341-1352
25. GarveyWT, Ryan DH, LookM, et al. Two-year sustainedweight loss andmetabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95:297-308
26. U.S. Food and Drug Administration. QSYMIA (phentermine and topiramate extended-release) capsules: risk evaluation and mitigation strategy [article online], 2013. Available from http://www .fda.gov/downloads/drugs/drugsafety/postmarket drugsafetyinformationforpatientsandproviders/ucm312598.pdf. Accessed 8 September 2014
27. Katsiki N, Hatzitolios AI, Mikhailidis DP. Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a newkid on the block'? Ann Med 2011;43: 249-258
28. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebocontrolled, phase 3 trial. Lancet 2010 21; 376:595-605
29. Apovian CM, Aronne L, Rubino D, et al.; COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013;21:935-943
30. Astrup A, Rössner S, Van Gaal L, et al.; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, doubleblind, placebo-controlled study. Lancet 2009;374: 1606-1616
31. Astrup A, Carraro R, Finer N, et al.; NN8022-1807 Investigators. Safety, tolerability and sustainedweight loss over 2 yearswith the once-daily human GLP-1 analog, liraglutide. Int J Obes 2012; 36:843-854
32. Davies MJ, Bergenstal R, Bode B, et al.; NN8022-1922 Study Group. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 2015;314:687-699
33. Pi-Sunyer X, Astrup A, Fujioka K, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22
34. Jendle J, Nauck MA, Matthews DR, et al.; LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagonlike peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009;11:1163-1172
35. Hiatt WR, Goldfine AB, Kaul S. Cardiovascular risk assessment in the development of new drugs for obesity. JAMA 2012;308:1099-1100
36. U.S. Food and Drug Administration. Guidance for industry: diabetesmellitusdevaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [article online], 2008. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 30 April 2014
37. Wilson JL, Enriori PJ. A talk between fat tissue, gut, pancreas and brain to control body weight. Mol Cell Endocrinol 2015;418:108-119
38. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-termmaintenance of weight loss after a very-low-calorie diet: a randomised blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179-184
39. Voils CI, Gierisch JM, Yancy WS Jr, et al. Differentiating behavior initiation and maintenance: theoretical framework and proof of concept. Health Educ Behav. 2014 Jun;41:325-336
40. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119-2125
41. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-1397
42. Van Gaal LF, Scheen AJ, Rissanen AM, Rössner S, Hanotin C, Ziegler O; RIO-Europe Study Group. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J 2008;29:1761-1771
43. Sjöström L, Rissanen A, Andersen T, et al.; European Multicentre Orlistat Study Group. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-172
44. Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G; European Orlistat Obesity Study Group. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000;8:49-61
45. Richelsen B, Tonstad S, Rössner S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care 2007;30:27-32
46. Smith SR, Weissman NJ, Anderson CM, et al.; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebocontrolled trial of lorcaserin for weight management. N Engl J Med 2010;363:245-256
47. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341-1352
48. Wadden TA, Hollander P, Klein S, et al.; NN8022-1923 Investigators. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes 2013;17:1443-1451
49. Astrup A, CatersonI, Zelissen P, et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004;12:1658-1669
50. van Baak MA, van Mil E, Astrup AV, et al.; STORMStudy Group. Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). Am J Clin Nutr 2003;78: 209-214
51. Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol 2014;2:911-922
52. Cefalu WT, Bray GA, Home PD, et al. Advances in the science treatment and prevention of the disease of obesity: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care 2015;38:1567-1582
53. Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DiO) rats. Obesity (Silver Spring) 2012;20:1645-1652
54. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75:33-59
55. Bolinder J, Ljunggren ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020-1031
56. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-382
57. Stenlöf K, CefaluWT, KimKA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014;30:163-175
58. Bays HE, Weinstein R, Law G, Canovatchel W. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) 2014;22:1042-1049
59. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodiumglucose cotransporter 2 inhibition. Diabetes Care 2015;38:1730-1735
60. Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care 2015;38: 1161-1172
61. Fulcher G, Matthews DR, Perkovic V, et al.; CANVAS trial collaborative group. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab 2016;18: 82-91
62. Cummings BP. Leptin therapy in type 2 diabetes. Diabetes Obes Metab 2013;15:607-612
63. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262-269
64. Grasso P. Novel approaches to the treatment of obesity and type 2 diabetes mellitus: bioactive leptin-related synthetic peptide analogs. Recent Pat Endocr Metab Immune Drug Discov 2011;5:163-175
65. Moon HS, Chamberland JP, Mantzoros CS. Amylin and leptin activate overlapping signalling pathways in an additive manner in mouse GT1-7 hypothalamic, C?C muscle and AML12 liver cell lines. Diabetologia 2012;55:215-225
66. Clemmensen C, Chabenne J, Finan B, et al. GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes 2014; 63:1422-1427
67. Finan B, Ma T, Ottaway N, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 2013;5:209ra151
68. Kim SJ, Nian C, Karunakaran S, Clee SM, Isales CM, McIntosh CH. GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS One 2012;7:e40156
69. Field BC, Wren AM, Peters V, et al. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010;59:1635-1639
70. Trevaskis JL, Sun C, Athanacio J, et al. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents. Diabetes Obes Metab 2015;17:61-73
71. Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 2015;21:27-36